A Tribute to Gordon Cragg
by James S. Miller ......................................... vii
Acknowledgments ................................................ ix
The Natural World: A Wealth of Chemical Diversity for Drug
Discovery
Marine-derived Compounds: New Frontiers in Production
by David J. Newman ........................................... 3
Amphibian Skin: A Remarkable Source of Biologically Active
Natural Products
by John W. Daly ............................................. 13
Bioprospecting Uncultured Microbial Biodiversity
by Boris Wawrik, Tinatin Doolotkeldieva,
Djumaniyaz Kutliev, Lee Kerkhof, Gerben J. Zylstra, and
Jerome J. Kukor ............................................. 21
Modern Innovations in Natural Products Research
Genomic Tools for the Discovery of Natural Products: What
Have We Missed?
by James B. McAlpine ........................................ 43
Pivotal Connections: Tracing Support by the Natural Products
Branch to Drug Discovery from Marine Organisms
by Eric Andrianasolo, Patricia M. Flatt, Kerry
F. McPhail, T. Luke Simmons, and William H. Gerwick ......... 55
Legal and Ethical Issues: From the Convention on Biological
Diversity to Conservation
Bioprospecting in the Cragg Era: Accomplishments and the
Road Ahead
by Michael J. Balick ........................................ 71
Two-tiered Systems for Access and Benefit-sharing Agreements
to Balance the Interests of Source Countries and Researchers
by Michael A. Gollin ........................................ 81
Envisioning Equality: Re-imagining the Political Economy of
Biological Resource Use
by Bronwyn Parry ............................................ 93
Transdisciplinary Team Science and Lessons from the
International Cooperative Biodiversity Groups
by Flora N. Katz and Joshua P. Rosenthal ................... 107
The Role of Natural Products in Future Drug Development
Nature's Potential: How Many Drugs Could Come from Plants?
by James S. Miller ......................................... 125
Natural Products as Sources for Drug Development: The Case
of Paclitaxel (Taxol)
by David G.I. Kingston ..................................... 141
Bioprospecting Endophytic Microbes
by Gary Strobel ............................................ 159
The Metabolic Versatility of the Methymycin/Pikromycin
Biosynthetic Pathway
by Jeffrey D. Kittendorf and David H. Sherman .............. 181
Index ......................................................... 191
|